25 XP   0   0   10

Novozymes AS
Buy, Hold or Sell?

Let's analyse Novozymes together

PenkeI guess you are interested in Novozymes AS. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Novozymes AS. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Novozymes AS

I send you an email if I find something interesting about Novozymes AS.

Quick analysis of Novozymes (30 sec.)










What can you expect buying and holding a share of Novozymes? (30 sec.)

How much money do you get?

How much money do you get?
$0.89
When do you have the money?
1 year
How often do you get paid?
80.0%

What is your share worth?

Current worth
$4.48
Expected worth in 1 year
$4.52
How sure are you?
95.0%

+ What do you gain per year?

Total Gains per Share
$0.93
Return On Investment
1.6%

For what price can you sell your share?

Current Price per Share
$58.86
Expected price per share
$54.31 - $63.19
How sure are you?
50%

1. Valuation of Novozymes (5 min.)




Live pricePrice per Share (EOD)

$58.86

Intrinsic Value Per Share

$2.05 - $6.42

Total Value Per Share

$6.53 - $10.90

2. Growth of Novozymes (5 min.)




Is Novozymes growing?

Current yearPrevious yearGrowGrow %
How rich?$2b$1.9b$140.6m6.9%

How much money is Novozymes making?

Current yearPrevious yearGrowGrow %
Making money$109.6m$133.2m-$23.6m-21.6%
Net Profit Margin16.9%20.9%--

How much money comes from the company's main activities?

3. Financial Health of Novozymes (5 min.)




4. Comparing to competitors in the Specialty Chemicals industry (5 min.)




  Industry Rankings (Specialty Chemicals)  


Richest
#69 / 565

Most Revenue
#97 / 565

Most Profit
#50 / 565

What can you expect buying and holding a share of Novozymes? (5 min.)

Welcome investor! Novozymes's management wants to use your money to grow the business. In return you get a share of Novozymes.

What can you expect buying and holding a share of Novozymes?

First you should know what it really means to hold a share of Novozymes. And how you can make/lose money.

Speculation

The Price per Share of Novozymes is $58.86. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Novozymes.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Novozymes, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $4.48. Based on the TTM, the Book Value Change Per Share is $0.01 per quarter. Based on the YOY, the Book Value Change Per Share is $0.16 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.22 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Novozymes.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.220.4%0.220.4%0.290.5%0.240.4%0.200.3%
Usd Book Value Change Per Share-0.17-0.3%0.010.0%0.160.3%0.050.1%0.030.0%
Usd Dividend Per Share0.370.6%0.220.4%0.120.2%0.230.4%0.170.3%
Usd Total Gains Per Share0.200.3%0.230.4%0.280.5%0.280.5%0.200.3%
Usd Price Per Share54.91-48.19-57.29-55.99-51.24-
Price to Earnings Ratio62.98-56.59-51.49-74.21-110.21-
Price-to-Total Gains Ratio268.88-226.02-357.16-576.51-2,692.34-
Price to Book Ratio12.25-11.00-14.24-15.06-14.30-
Price-to-Total Gains Ratio268.88-226.02-357.16-576.51-2,692.34-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share58.86
Number of shares16
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.220.23
Usd Book Value Change Per Share0.010.05
Usd Total Gains Per Share0.230.28
Gains per Quarter (16 shares)3.724.41
Gains per Year (16 shares)14.8917.65
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
114151538
22912029626
34323544944
457250591262
571365741580
686480881798
710049510320116
8114511011823134
9128612513326152
10143614014729170

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%58.00.00.0100.0%
Book Value Change Per Share2.02.00.050.0%8.04.00.066.7%13.07.00.065.0%25.015.00.062.5%39.016.03.067.2%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%18.00.02.090.0%32.00.08.080.0%37.00.021.063.8%
Total Gains per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%38.02.00.095.0%53.02.03.091.4%

Fundamentals of Novozymes

About Novozymes AS

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services. In addition, the company provides dishwashing, softener, microbial and medical cleaning services. Further, it provides corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; warm water species, recirculating aquaculture system; animal health and nutrition solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions. Additionally, the company provides carbon capture, leather and textiles solutions; enzyme solutions, including corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; warm water species and recirculating aquaculture system solutions; human health solutions, comprising brain, oral, protective and immune, and gastrointestinal health solutions; ethanol, biodiesel, renewable diesel, education, wastewater, and sewage sludge, and renewable diesel solutions; agriculture and industry, biogas food waste, food waste, biocatalysis, cell culture, diagnostics, enzyme, and biogas solutions. Furthermore, it provides lipases, proteases, oxidoreductases, and carbohydrases. Novozymes A/S was founded in 1925 and is based in Bagsvaerd, Denmark.

Fundamental data was last updated by Penke on 2024-03-12 01:41:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Novozymes AS.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Novozymes earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Novozymes to the Specialty Chemicals industry mean.
  • A Net Profit Margin of 15.2% means that $0.15 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Novozymes AS:

  • The MRQ is 15.2%. The company is making a huge profit. +2
  • The TTM is 16.9%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ15.2%TTM16.9%-1.7%
TTM16.9%YOY20.9%-4.1%
TTM16.9%5Y20.2%-3.3%
5Y20.2%10Y20.7%-0.5%
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ15.2%4.2%+11.0%
TTM16.9%4.2%+12.7%
YOY20.9%6.4%+14.5%
5Y20.2%6.0%+14.2%
10Y20.7%6.0%+14.7%
1.1.2. Return on Assets

Shows how efficient Novozymes is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Novozymes to the Specialty Chemicals industry mean.
  • 2.5% Return on Assets means that Novozymes generated $0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Novozymes AS:

  • The MRQ is 2.5%. Using its assets, the company is less efficient in making profit.
  • The TTM is 2.7%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ2.5%TTM2.7%-0.2%
TTM2.7%YOY3.4%-0.7%
TTM2.7%5Y3.4%-0.7%
5Y3.4%10Y3.7%-0.3%
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ2.5%1.1%+1.4%
TTM2.7%1.1%+1.6%
YOY3.4%1.7%+1.7%
5Y3.4%1.6%+1.8%
10Y3.7%1.7%+2.0%
1.1.3. Return on Equity

Shows how efficient Novozymes is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Novozymes to the Specialty Chemicals industry mean.
  • 5.0% Return on Equity means Novozymes generated $0.05 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Novozymes AS:

  • The MRQ is 5.0%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 5.5%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ5.0%TTM5.5%-0.5%
TTM5.5%YOY7.2%-1.7%
TTM5.5%5Y6.7%-1.1%
5Y6.7%10Y6.7%0.0%
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ5.0%2.2%+2.8%
TTM5.5%2.0%+3.5%
YOY7.2%3.2%+4.0%
5Y6.7%2.7%+4.0%
10Y6.7%2.8%+3.9%

1.2. Operating Efficiency of Novozymes AS.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Novozymes is operating .

  • Measures how much profit Novozymes makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Novozymes to the Specialty Chemicals industry mean.
  • An Operating Margin of 33.3% means the company generated $0.33  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Novozymes AS:

  • The MRQ is 33.3%. The company is operating very efficient. +2
  • The TTM is 25.3%. The company is operating very efficient. +2
Trends
Current periodCompared to+/- 
MRQ33.3%TTM25.3%+8.0%
TTM25.3%YOY23.7%+1.6%
TTM25.3%5Y26.2%-0.9%
5Y26.2%10Y23.9%+2.3%
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ33.3%7.5%+25.8%
TTM25.3%4.8%+20.5%
YOY23.7%8.2%+15.5%
5Y26.2%8.1%+18.1%
10Y23.9%7.3%+16.6%
1.2.2. Operating Ratio

Measures how efficient Novozymes is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Specialty Chemicals industry mean).
  • An Operation Ratio of 0.77 means that the operating costs are $0.77 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Novozymes AS:

  • The MRQ is 0.768. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.751. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.768TTM0.751+0.017
TTM0.751YOY0.747+0.003
TTM0.7515Y0.746+0.004
5Y0.74610Y0.736+0.011
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7681.529-0.761
TTM0.7511.530-0.779
YOY0.7471.459-0.712
5Y0.7461.462-0.716
10Y0.7361.229-0.493

1.3. Liquidity of Novozymes AS.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Novozymes is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Specialty Chemicals industry mean).
  • A Current Ratio of 1.30 means the company has $1.30 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Novozymes AS:

  • The MRQ is 1.303. The company is just able to pay all its short-term debts.
  • The TTM is 1.385. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.303TTM1.385-0.082
TTM1.385YOY1.252+0.133
TTM1.3855Y1.390-0.005
5Y1.39010Y1.505-0.115
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3031.831-0.528
TTM1.3851.875-0.490
YOY1.2521.896-0.644
5Y1.3901.926-0.536
10Y1.5051.762-0.257
1.3.2. Quick Ratio

Measures if Novozymes is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Novozymes to the Specialty Chemicals industry mean.
  • A Quick Ratio of 0.68 means the company can pay off $0.68 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Novozymes AS:

  • The MRQ is 0.684. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.800. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.684TTM0.800-0.116
TTM0.800YOY0.760+0.040
TTM0.8005Y0.832-0.032
5Y0.83210Y0.628+0.204
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6840.846-0.162
TTM0.8000.884-0.084
YOY0.7600.966-0.206
5Y0.8321.049-0.217
10Y0.6281.030-0.402

1.4. Solvency of Novozymes AS.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Novozymes assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Novozymes to Specialty Chemicals industry mean.
  • A Debt to Asset Ratio of 0.49 means that Novozymes assets are financed with 49.5% credit (debt) and the remaining percentage (100% - 49.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Novozymes AS:

  • The MRQ is 0.495. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.504. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.495TTM0.504-0.009
TTM0.504YOY0.514-0.010
TTM0.5045Y0.485+0.018
5Y0.48510Y0.442+0.043
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4950.431+0.064
TTM0.5040.427+0.077
YOY0.5140.426+0.088
5Y0.4850.433+0.052
10Y0.4420.439+0.003
1.4.2. Debt to Equity Ratio

Measures if Novozymes is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Novozymes to the Specialty Chemicals industry mean.
  • A Debt to Equity ratio of 100.4% means that company has $1.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Novozymes AS:

  • The MRQ is 1.004. The company is able to pay all its debts with equity. +1
  • The TTM is 1.047. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.004TTM1.047-0.043
TTM1.047YOY1.094-0.046
TTM1.0475Y0.964+0.083
5Y0.96410Y0.816+0.148
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0040.767+0.237
TTM1.0470.752+0.295
YOY1.0940.747+0.347
5Y0.9640.797+0.167
10Y0.8160.845-0.029

2. Market Valuation of Novozymes AS

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Novozymes generates.

  • Above 15 is considered overpriced but always compare Novozymes to the Specialty Chemicals industry mean.
  • A PE ratio of 62.98 means the investor is paying $62.98 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Novozymes AS:

  • The EOD is 67.513. Based on the earnings, the company is expensive. -2
  • The MRQ is 62.982. Based on the earnings, the company is expensive. -2
  • The TTM is 56.593. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD67.513MRQ62.982+4.531
MRQ62.982TTM56.593+6.389
TTM56.593YOY51.489+5.104
TTM56.5935Y74.214-17.621
5Y74.21410Y110.207-35.993
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
EOD67.51315.013+52.500
MRQ62.98213.988+48.994
TTM56.59315.705+40.888
YOY51.48917.841+33.648
5Y74.21419.498+54.716
10Y110.20723.950+86.257
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Novozymes AS:

  • The EOD is 90.973. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The MRQ is 84.868. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is -45.203. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD90.973MRQ84.868+6.105
MRQ84.868TTM-45.203+130.071
TTM-45.203YOY45.902-91.104
TTM-45.2035Y77.054-122.257
5Y77.05410Y62.101+14.953
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
EOD90.9735.077+85.896
MRQ84.8684.568+80.300
TTM-45.2032.302-47.505
YOY45.902-0.150+46.052
5Y77.0543.140+73.914
10Y62.1012.653+59.448
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Novozymes is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Specialty Chemicals industry mean).
  • A PB ratio of 12.25 means the investor is paying $12.25 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Novozymes AS:

  • The EOD is 13.135. Based on the equity, the company is expensive. -2
  • The MRQ is 12.253. Based on the equity, the company is expensive. -2
  • The TTM is 11.005. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD13.135MRQ12.253+0.881
MRQ12.253TTM11.005+1.248
TTM11.005YOY14.241-3.236
TTM11.0055Y15.055-4.050
5Y15.05510Y14.303+0.753
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
EOD13.1351.713+11.422
MRQ12.2531.781+10.472
TTM11.0051.854+9.151
YOY14.2412.306+11.935
5Y15.0552.351+12.704
10Y14.3032.842+11.461
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Novozymes AS compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.1680.010-1853%0.158-207%0.045-470%0.026-756%
Book Value Per Share--4.4814.397+2%4.094+9%3.787+18%3.613+24%
Current Ratio--1.3031.385-6%1.252+4%1.390-6%1.505-13%
Debt To Asset Ratio--0.4950.504-2%0.514-4%0.485+2%0.442+12%
Debt To Equity Ratio--1.0041.047-4%1.094-8%0.964+4%0.816+23%
Dividend Per Share--0.3730.223+67%0.119+213%0.230+62%0.175+113%
Eps--0.2180.222-2%0.287-24%0.235-7%0.196+11%
Free Cash Flow Per Share--0.1620.164-1%0.087+86%0.182-11%0.195-17%
Free Cash Flow To Equity Per Share---0.0120.016-171%-0.010-9%0.031-138%0.012-198%
Gross Profit Margin--0.1390.194-28%0.370-62%0.366-62%0.418-67%
Intrinsic Value_10Y_max--6.418--------
Intrinsic Value_10Y_min--2.050--------
Intrinsic Value_1Y_max--0.763--------
Intrinsic Value_1Y_min--0.560--------
Intrinsic Value_3Y_max--2.201--------
Intrinsic Value_3Y_min--1.385--------
Intrinsic Value_5Y_max--3.529--------
Intrinsic Value_5Y_min--1.878--------
Market Cap27331994160.000+7%25497787960.00022377315640.000+14%26600633460.000-4%25998770039.500-2%23795023530.250+7%
Net Profit Margin--0.1520.169-10%0.209-28%0.202-25%0.207-27%
Operating Margin--0.3330.253+31%0.237+40%0.262+27%0.239+39%
Operating Ratio--0.7680.751+2%0.747+3%0.746+3%0.736+4%
Pb Ratio13.135+7%12.25311.005+11%14.241-14%15.055-19%14.303-14%
Pe Ratio67.513+7%62.98256.593+11%51.489+22%74.214-15%110.207-43%
Price Per Share58.860+7%54.91048.190+14%57.285-4%55.989-2%51.243+7%
Price To Free Cash Flow Ratio90.973+7%84.868-45.203+153%45.902+85%77.054+10%62.101+37%
Price To Total Gains Ratio288.221+7%268.879226.017+19%357.163-25%576.506-53%2692.341-90%
Quick Ratio--0.6840.800-14%0.760-10%0.832-18%0.628+9%
Return On Assets--0.0250.027-8%0.034-28%0.034-27%0.037-34%
Return On Equity--0.0500.055-9%0.072-31%0.067-25%0.067-25%
Total Gains Per Share--0.2040.233-12%0.277-26%0.276-26%0.200+2%
Usd Book Value--2080895000.0002041817500.000+2%1901203750.000+9%1758284500.000+18%1677693500.000+24%
Usd Book Value Change Per Share---0.1680.010-1853%0.158-207%0.045-470%0.026-756%
Usd Book Value Per Share--4.4814.397+2%4.094+9%3.787+18%3.613+24%
Usd Dividend Per Share--0.3730.223+67%0.119+213%0.230+62%0.175+113%
Usd Eps--0.2180.222-2%0.287-24%0.235-7%0.196+11%
Usd Free Cash Flow--75110000.00075980000.000-1%40455000.000+86%84448000.000-11%90770000.000-17%
Usd Free Cash Flow Per Share--0.1620.164-1%0.087+86%0.182-11%0.195-17%
Usd Free Cash Flow To Equity Per Share---0.0120.016-171%-0.010-9%0.031-138%0.012-198%
Usd Market Cap27331994160.000+7%25497787960.00022377315640.000+14%26600633460.000-4%25998770039.500-2%23795023530.250+7%
Usd Price Per Share58.860+7%54.91048.190+14%57.285-4%55.989-2%51.243+7%
Usd Profit--101210000.000109620000.000-8%133255000.000-24%114731250.000-12%110812625.000-9%
Usd Revenue--667435000.000648838750.000+3%636296250.000+5%571220250.000+17%537634625.000+24%
Usd Total Gains Per Share--0.2040.233-12%0.277-26%0.276-26%0.200+2%
 EOD+4 -4MRQTTM+13 -23YOY+15 -215Y+10 -2610Y+17 -19

3.2. Fundamental Score

Let's check the fundamental score of Novozymes AS based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1567.513
Price to Book Ratio (EOD)Between0-113.135
Net Profit Margin (MRQ)Greater than00.152
Operating Margin (MRQ)Greater than00.333
Quick Ratio (MRQ)Greater than10.684
Current Ratio (MRQ)Greater than11.303
Debt to Asset Ratio (MRQ)Less than10.495
Debt to Equity Ratio (MRQ)Less than11.004
Return on Equity (MRQ)Greater than0.150.050
Return on Assets (MRQ)Greater than0.050.025
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Novozymes AS based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose59.050
Total1/1 (100.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Depreciation and Amortization  4,20514,93519,140-2,17516,96530,01546,980-118,030-71,050



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in DKK. All numbers in thousands.

Summary
Total Assets28,391,000
Total Liabilities14,040,000
Total Stockholder Equity13,978,000
 As reported
Total Liabilities 14,040,000
Total Stockholder Equity+ 13,978,000
Total Assets = 28,391,000

Assets

Total Assets28,391,000
Total Current Assets9,462,000
Long-term Assets18,929,000
Total Current Assets
Cash And Cash Equivalents 1,116,000
Short-term Investments 40,000
Net Receivables 3,772,000
Inventory 3,627,000
Other Current Assets 947,000
Total Current Assets  (as reported)9,462,000
Total Current Assets  (calculated)9,502,000
+/- 40,000
Long-term Assets
Property Plant Equipment 12,325,000
Goodwill 1,975,000
Intangible Assets 2,557,000
Long-term Assets Other 83,000
Long-term Assets  (as reported)18,929,000
Long-term Assets  (calculated)16,940,000
+/- 1,989,000

Liabilities & Shareholders' Equity

Total Current Liabilities7,262,000
Long-term Liabilities6,778,000
Total Stockholder Equity13,978,000
Total Current Liabilities
Short-term Debt 137,000
Accounts payable 1,616,000
Other Current Liabilities 656,000
Total Current Liabilities  (as reported)7,262,000
Total Current Liabilities  (calculated)2,409,000
+/- 4,853,000
Long-term Liabilities
Capital Lease Obligations 369,000
Long-term Liabilities  (as reported)6,778,000
Long-term Liabilities  (calculated)369,000
+/- 6,409,000
Total Stockholder Equity
Common Stock562,000
Retained Earnings 13,755,000
Other Stockholders Equity -339,000
Total Stockholder Equity (as reported)13,978,000
Total Stockholder Equity (calculated)13,978,000
+/-0
Other
Capital Stock562,000
Cash and Short Term Investments 1,156,000
Common Stock Shares Outstanding 277,875
Current Deferred Revenue4,853,000
Liabilities and Stockholders Equity 28,391,000
Net Debt -747,000
Net Invested Capital 13,978,000
Net Working Capital 2,200,000
Property Plant and Equipment Gross 26,219,000
Short Long Term Debt Total 369,000



Balance Sheet

Currency in DKK. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-31
> Total Assets 
0
0
0
10,890,000
11,118,000
11,421,000
11,719,000
12,593,000
13,115,000
13,176,000
13,646,000
13,842,000
13,671,000
14,163,000
14,541,000
15,113,000
16,164,000
16,101,000
15,924,000
16,506,000
17,681,000
18,213,000
18,868,000
18,426,000
18,471,000
18,326,000
17,916,000
17,791,000
17,529,000
17,757,000
17,814,000
18,659,000
18,865,000
18,060,000
18,057,000
18,373,000
18,532,000
18,858,000
18,997,000
19,697,000
20,391,000
20,059,000
20,152,000
20,437,000
20,423,000
20,709,000
20,127,000
20,510,000
21,684,000
21,617,000
21,826,000
24,767,000
25,277,000
26,495,000
27,975,000
27,983,000
28,284,000
28,228,000
28,538,000
28,391,000
28,391,00028,538,00028,228,00028,284,00027,983,00027,975,00026,495,00025,277,00024,767,00021,826,00021,617,00021,684,00020,510,00020,127,00020,709,00020,423,00020,437,00020,152,00020,059,00020,391,00019,697,00018,997,00018,858,00018,532,00018,373,00018,057,00018,060,00018,865,00018,659,00017,814,00017,757,00017,529,00017,791,00017,916,00018,326,00018,471,00018,426,00018,868,00018,213,00017,681,00016,506,00015,924,00016,101,00016,164,00015,113,00014,541,00014,163,00013,671,00013,842,00013,646,00013,176,00013,115,00012,593,00011,719,00011,421,00011,118,00010,890,000000
   > Total Current Assets 
0
0
0
4,899,000
4,861,000
4,688,000
5,061,000
5,536,000
4,834,000
4,807,000
5,025,000
4,789,000
4,743,000
4,831,000
5,181,000
4,890,000
5,378,000
5,264,000
5,317,000
5,830,000
6,966,000
7,553,000
7,903,000
7,311,000
6,687,000
6,867,000
6,518,000
6,148,000
6,250,000
6,218,000
6,076,000
6,393,000
6,653,000
6,146,000
6,258,000
6,137,000
6,507,000
6,442,000
6,658,000
6,835,000
6,771,000
6,809,000
6,835,000
7,050,000
7,180,000
6,861,000
6,582,000
6,911,000
7,012,000
7,075,000
7,189,000
7,823,000
8,321,000
8,560,000
9,321,000
9,241,000
9,591,000
9,374,000
9,441,000
9,462,000
9,462,0009,441,0009,374,0009,591,0009,241,0009,321,0008,560,0008,321,0007,823,0007,189,0007,075,0007,012,0006,911,0006,582,0006,861,0007,180,0007,050,0006,835,0006,809,0006,771,0006,835,0006,658,0006,442,0006,507,0006,137,0006,258,0006,146,0006,653,0006,393,0006,076,0006,218,0006,250,0006,148,0006,518,0006,867,0006,687,0007,311,0007,903,0007,553,0006,966,0005,830,0005,317,0005,264,0005,378,0004,890,0005,181,0004,831,0004,743,0004,789,0005,025,0004,807,0004,834,0005,536,0005,061,0004,688,0004,861,0004,899,000000
       Cash And Cash Equivalents 
0
0
0
1,284,000
1,237,000
1,016,000
1,490,000
1,465,000
435,000
536,000
610,000
667,000
383,000
415,000
572,000
535,000
420,000
395,000
473,000
1,003,000
2,153,000
2,840,000
3,072,000
2,535,000
1,172,000
1,522,000
1,095,000
839,000
732,000
711,000
675,000
812,000
754,000
647,000
661,000
632,000
716,000
501,000
582,000
723,000
727,000
910,000
651,000
711,000
926,000
1,024,000
856,000
1,181,000
1,063,000
969,000
863,000
963,000
1,097,000
1,013,000
1,377,000
1,041,000
1,100,000
1,048,000
1,175,000
1,116,000
1,116,0001,175,0001,048,0001,100,0001,041,0001,377,0001,013,0001,097,000963,000863,000969,0001,063,0001,181,000856,0001,024,000926,000711,000651,000910,000727,000723,000582,000501,000716,000632,000661,000647,000754,000812,000675,000711,000732,000839,0001,095,0001,522,0001,172,0002,535,0003,072,0002,840,0002,153,0001,003,000473,000395,000420,000535,000572,000415,000383,000667,000610,000536,000435,0001,465,0001,490,0001,016,0001,237,0001,284,000000
       Short-term Investments 
0
0
0
0
84,000
37,000
161,000
178,000
387,000
319,000
0
48,000
122,000
15,000
120,000
45,000
22,000
14,000
106,000
87,000
70,000
43,000
31,000
17,000
57,000
42,000
50,000
20,000
62,000
12,000
9,000
4,000
11,000
35,000
38,000
16,000
52,000
45,000
6,000
14,000
27,000
19,000
22,000
15,000
23,000
22,000
78,000
119,000
25,000
28,000
41,000
75,000
97,000
64,000
107,000
80,000
84,000
63,000
16,000
40,000
40,00016,00063,00084,00080,000107,00064,00097,00075,00041,00028,00025,000119,00078,00022,00023,00015,00022,00019,00027,00014,0006,00045,00052,00016,00038,00035,00011,0004,0009,00012,00062,00020,00050,00042,00057,00017,00031,00043,00070,00087,000106,00014,00022,00045,000120,00015,000122,00048,0000319,000387,000178,000161,00037,00084,0000000
       Net Receivables 
0
0
0
1,893,000
0
0
0
0
0
0
2,477,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,089,000
3,377,000
446,220
460,922
468,097
513,765
491,089
504,340
503,440
2,547,000
2,492,000
2,736,000
3,649,000
3,648,000
3,169,000
3,098,000
3,227,000
3,470,000
3,366,000
3,413,000
3,793,000
4,045,000
4,017,000
4,080,000
4,143,000
4,556,000
4,301,000
4,372,000
3,772,000
3,772,0004,372,0004,301,0004,556,0004,143,0004,080,0004,017,0004,045,0003,793,0003,413,0003,366,0003,470,0003,227,0003,098,0003,169,0003,648,0003,649,0002,736,0002,492,0002,547,000503,440504,340491,089513,765468,097460,922446,2203,377,0003,089,000000000000000000000002,477,0000000001,893,000000
       Other Current Assets 
0
0
0
187,000
1,969,000
2,078,000
1,906,000
2,253,000
2,369,000
2,240,000
210,000
2,333,000
2,479,000
2,673,000
2,712,000
2,502,000
2,966,000
2,877,000
2,768,000
2,838,000
2,847,000
2,744,000
2,764,000
2,575,000
3,166,000
2,956,000
3,051,000
3,008,000
3,246,000
3,154,000
2,970,000
3,089,000
3,377,000
2,904,000
2,924,000
2,903,000
3,111,000
3,144,000
3,248,000
3,278,000
3,209,000
3,100,000
3,361,000
3,711,000
3,671,000
3,191,000
3,120,000
3,250,000
3,481,000
3,377,000
3,425,000
3,793,000
4,045,000
4,017,000
4,080,000
4,317,000
801,000
598,000
616,000
947,000
947,000616,000598,000801,0004,317,0004,080,0004,017,0004,045,0003,793,0003,425,0003,377,0003,481,0003,250,0003,120,0003,191,0003,671,0003,711,0003,361,0003,100,0003,209,0003,278,0003,248,0003,144,0003,111,0002,903,0002,924,0002,904,0003,377,0003,089,0002,970,0003,154,0003,246,0003,008,0003,051,0002,956,0003,166,0002,575,0002,764,0002,744,0002,847,0002,838,0002,768,0002,877,0002,966,0002,502,0002,712,0002,673,0002,479,0002,333,000210,0002,240,0002,369,0002,253,0001,906,0002,078,0001,969,000187,000000
   > Long-term Assets 
0
0
0
5,991,000
6,257,000
6,733,000
6,658,000
7,057,000
8,281,000
8,369,000
8,621,000
9,053,000
8,928,000
9,332,000
9,360,000
10,223,000
10,786,000
10,837,000
10,607,000
10,676,000
10,715,000
10,660,000
10,965,000
11,115,000
11,784,000
11,459,000
11,398,000
11,643,000
11,279,000
11,539,000
11,738,000
12,266,000
12,212,000
11,914,000
11,799,000
12,236,000
12,025,000
12,416,000
12,339,000
12,862,000
13,620,000
13,250,000
13,317,000
13,387,000
13,243,000
13,848,000
13,545,000
13,599,000
14,672,000
14,542,000
14,637,000
16,944,000
16,956,000
17,935,000
18,654,000
18,742,000
18,693,000
18,854,000
19,097,000
18,929,000
18,929,00019,097,00018,854,00018,693,00018,742,00018,654,00017,935,00016,956,00016,944,00014,637,00014,542,00014,672,00013,599,00013,545,00013,848,00013,243,00013,387,00013,317,00013,250,00013,620,00012,862,00012,339,00012,416,00012,025,00012,236,00011,799,00011,914,00012,212,00012,266,00011,738,00011,539,00011,279,00011,643,00011,398,00011,459,00011,784,00011,115,00010,965,00010,660,00010,715,00010,676,00010,607,00010,837,00010,786,00010,223,0009,360,0009,332,0008,928,0009,053,0008,621,0008,369,0008,281,0007,057,0006,658,0006,733,0006,257,0005,991,000000
       Property Plant Equipment 
0
0
0
4,804,000
5,038,000
5,489,000
5,353,000
5,866,000
5,795,000
5,938,000
6,248,000
6,557,000
6,459,000
6,872,000
6,929,000
7,084,000
7,299,000
7,238,000
7,166,000
7,135,000
6,955,000
6,972,000
7,307,000
7,498,000
8,098,000
7,887,000
7,871,000
8,162,000
7,929,000
8,207,000
8,239,000
8,641,000
8,663,000
8,507,000
8,564,000
8,926,000
8,885,000
9,258,000
9,302,000
9,698,000
10,376,000
10,232,000
10,321,000
10,212,000
10,103,000
9,952,000
9,717,000
9,612,000
9,736,000
9,681,000
9,755,000
10,185,000
10,436,000
11,254,000
11,962,000
12,074,000
12,138,000
12,335,000
12,679,000
12,325,000
12,325,00012,679,00012,335,00012,138,00012,074,00011,962,00011,254,00010,436,00010,185,0009,755,0009,681,0009,736,0009,612,0009,717,0009,952,00010,103,00010,212,00010,321,00010,232,00010,376,0009,698,0009,302,0009,258,0008,885,0008,926,0008,564,0008,507,0008,663,0008,641,0008,239,0008,207,0007,929,0008,162,0007,871,0007,887,0008,098,0007,498,0007,307,0006,972,0006,955,0007,135,0007,166,0007,238,0007,299,0007,084,0006,929,0006,872,0006,459,0006,557,0006,248,0005,938,0005,795,0005,866,0005,353,0005,489,0005,038,0004,804,000000
       Goodwill 
0
0
0
0
479,000
504,000
492,000
0
813,000
816,000
840,000
0
825,000
834,000
0
811,000
884,000
902,000
1,082,000
1,022,000
1,044,000
1,048,000
1,072,000
1,113,000
1,167,000
1,144,000
1,128,000
1,140,000
1,116,000
1,122,000
1,140,000
1,159,000
1,163,000
1,132,000
1,117,000
1,108,000
1,089,000
1,090,000
111,000
1,086,000
1,093,000
967,000
971,000
965,000
963,000
1,120,000
1,106,000
1,098,000
1,537,000
1,493,000
1,506,000
2,020,000
2,049,000
2,081,000
2,107,000
2,007,000
1,995,000
1,997,000
2,011,000
1,975,000
1,975,0002,011,0001,997,0001,995,0002,007,0002,107,0002,081,0002,049,0002,020,0001,506,0001,493,0001,537,0001,098,0001,106,0001,120,000963,000965,000971,000967,0001,093,0001,086,000111,0001,090,0001,089,0001,108,0001,117,0001,132,0001,163,0001,159,0001,140,0001,122,0001,116,0001,140,0001,128,0001,144,0001,167,0001,113,0001,072,0001,048,0001,044,0001,022,0001,082,000902,000884,000811,0000834,000825,0000840,000816,000813,0000492,000504,000479,0000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
224,000
210,000
31,346
22,069
14,190
16,019
13,121
12,577
9,522
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000009,52212,57713,12116,01914,19022,06931,346210,000224,0000000000000000000000000000000000
       Intangible Assets 
0
0
0
1,124,000
674,000
664,000
634,000
1,070,000
1,527,000
1,477,000
1,436,000
2,221,000
1,344,000
1,316,000
0
1,861,000
2,131,000
2,279,000
1,971,000
1,842,000
2,007,000
1,934,000
1,867,000
1,841,000
1,807,000
1,751,000
1,707,000
1,536,000
1,473,000
1,457,000
1,642,000
1,578,000
1,533,000
1,465,000
1,402,000
1,324,000
1,245,000
1,198,000
2,062,000
1,044,000
1,011,000
1,005,000
971,000
961,000
937,000
1,548,000
1,510,000
1,456,000
2,172,000
2,080,000
2,038,000
3,004,000
2,923,000
2,886,000
2,848,000
2,691,000
2,604,000
2,567,000
2,551,000
2,557,000
2,557,0002,551,0002,567,0002,604,0002,691,0002,848,0002,886,0002,923,0003,004,0002,038,0002,080,0002,172,0001,456,0001,510,0001,548,000937,000961,000971,0001,005,0001,011,0001,044,0002,062,0001,198,0001,245,0001,324,0001,402,0001,465,0001,533,0001,578,0001,642,0001,457,0001,473,0001,536,0001,707,0001,751,0001,807,0001,841,0001,867,0001,934,0002,007,0001,842,0001,971,0002,279,0002,131,0001,861,00001,316,0001,344,0002,221,0001,436,0001,477,0001,527,0001,070,000634,000664,000674,0001,124,000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
664,000
643,000
93,116
90,797
127,384
117,088
122,772
121,582
149,281
162,073
987,000
995,000
1,190,000
1,181,000
1,170,000
1,156,000
1,379,000
1,174,000
1,228,000
1,278,000
1,676,000
1,488,000
1,602,000
1,463,000
1,747,000
1,738,000
1,736,000
0
0
001,736,0001,738,0001,747,0001,463,0001,602,0001,488,0001,676,0001,278,0001,228,0001,174,0001,379,0001,156,0001,170,0001,181,0001,190,000995,000987,000162,073149,281121,582122,772117,088127,38490,79793,116643,000664,0000000000000000000000000000000000
> Total Liabilities 
0
0
0
5,039,000
4,987,000
4,660,000
4,420,000
4,757,000
5,359,000
5,060,000
5,270,000
5,018,000
5,058,000
5,299,000
5,335,000
5,545,000
6,513,000
6,042,000
5,334,000
5,440,000
7,031,000
7,380,000
7,790,000
7,146,000
7,203,000
7,130,000
6,819,000
6,198,000
6,896,000
6,794,000
6,842,000
6,914,000
7,911,000
7,384,000
7,321,000
7,106,000
8,299,000
8,138,000
8,039,000
8,259,000
9,463,000
9,037,000
8,948,000
8,957,000
9,659,000
9,893,000
9,316,000
9,266,000
10,902,000
10,703,000
10,248,000
12,561,000
13,594,000
14,002,000
13,932,000
13,755,000
14,998,000
14,429,000
13,648,000
14,040,000
14,040,00013,648,00014,429,00014,998,00013,755,00013,932,00014,002,00013,594,00012,561,00010,248,00010,703,00010,902,0009,266,0009,316,0009,893,0009,659,0008,957,0008,948,0009,037,0009,463,0008,259,0008,039,0008,138,0008,299,0007,106,0007,321,0007,384,0007,911,0006,914,0006,842,0006,794,0006,896,0006,198,0006,819,0007,130,0007,203,0007,146,0007,790,0007,380,0007,031,0005,440,0005,334,0006,042,0006,513,0005,545,0005,335,0005,299,0005,058,0005,018,0005,270,0005,060,0005,359,0004,757,0004,420,0004,660,0004,987,0005,039,000000
   > Total Current Liabilities 
0
0
0
2,521,000
2,597,000
2,248,000
2,132,000
2,508,000
2,996,000
2,681,000
2,848,000
2,357,000
2,955,000
3,143,000
3,253,000
2,620,000
3,492,000
2,937,000
2,296,000
2,599,000
3,387,000
3,867,000
4,379,000
3,941,000
4,070,000
4,150,000
3,813,000
3,300,000
3,992,000
3,457,000
3,410,000
3,562,000
4,504,000
4,138,000
4,223,000
4,577,000
5,036,000
4,995,000
5,117,000
5,525,000
5,560,000
5,353,000
5,307,000
4,735,000
4,696,000
4,800,000
4,283,000
4,161,000
5,050,000
4,930,000
4,413,000
5,673,000
6,937,000
7,162,000
7,244,000
6,963,000
7,116,000
6,836,000
6,223,000
7,262,000
7,262,0006,223,0006,836,0007,116,0006,963,0007,244,0007,162,0006,937,0005,673,0004,413,0004,930,0005,050,0004,161,0004,283,0004,800,0004,696,0004,735,0005,307,0005,353,0005,560,0005,525,0005,117,0004,995,0005,036,0004,577,0004,223,0004,138,0004,504,0003,562,0003,410,0003,457,0003,992,0003,300,0003,813,0004,150,0004,070,0003,941,0004,379,0003,867,0003,387,0002,599,0002,296,0002,937,0003,492,0002,620,0003,253,0003,143,0002,955,0002,357,0002,848,0002,681,0002,996,0002,508,0002,132,0002,248,0002,597,0002,521,000000
       Short-term Debt 
0
0
0
0
621,000
367,000
227,000
0
0
442,000
339,000
0
778,000
965,000
751,000
243,000
984,000
565,000
110,000
92,000
477,000
540,000
574,000
594,000
154,000
234,000
83,000
74,000
785,000
130,000
96,000
89,000
905,000
801,000
630,000
971,000
1,294,000
1,423,000
1,128,000
1,789,000
131,000
129,000
136,000
1,543,000
154,000
151,000
139,000
136,000
135,000
156,000
156,000
122,000
124,000
128,000
139,000
123,000
126,000
122,000
116,000
137,000
137,000116,000122,000126,000123,000139,000128,000124,000122,000156,000156,000135,000136,000139,000151,000154,0001,543,000136,000129,000131,0001,789,0001,128,0001,423,0001,294,000971,000630,000801,000905,00089,00096,000130,000785,00074,00083,000234,000154,000594,000574,000540,000477,00092,000110,000565,000984,000243,000751,000965,000778,0000339,000442,00000227,000367,000621,0000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,803,000
2,618,000
382,452
99,310
156,570
213,697
222,271
175,153
274,757
2,103,000
1,851,000
1,551,000
0
1,616,000
1,695,000
1,431,000
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000001,431,0001,695,0001,616,00001,551,0001,851,0002,103,000274,757175,153222,271213,697156,57099,310382,4522,618,0001,803,0000000000000000000000000000000000
       Accounts payable 
0
0
0
531,000
478,000
513,000
556,000
764,000
656,000
652,000
683,000
745,000
734,000
672,000
844,000
1,044,000
932,000
851,000
690,000
976,000
777,000
941,000
884,000
1,122,000
1,051,000
1,438,000
1,064,000
1,189,000
932,000
1,060,000
1,006,000
1,194,000
1,167,000
1,134,000
1,191,000
1,341,000
1,241,000
1,190,000
1,259,000
1,418,000
1,111,000
1,097,000
1,040,000
1,117,000
1,078,000
1,112,000
992,000
1,100,000
1,163,000
1,144,000
1,162,000
1,490,000
1,440,000
1,597,000
1,816,000
1,869,000
1,452,000
1,321,000
1,460,000
1,616,000
1,616,0001,460,0001,321,0001,452,0001,869,0001,816,0001,597,0001,440,0001,490,0001,162,0001,144,0001,163,0001,100,000992,0001,112,0001,078,0001,117,0001,040,0001,097,0001,111,0001,418,0001,259,0001,190,0001,241,0001,341,0001,191,0001,134,0001,167,0001,194,0001,006,0001,060,000932,0001,189,0001,064,0001,438,0001,051,0001,122,000884,000941,000777,000976,000690,000851,000932,0001,044,000844,000672,000734,000745,000683,000652,000656,000764,000556,000513,000478,000531,000000
       Other Current Liabilities 
0
0
0
1,990,000
1,415,000
1,275,000
1,307,000
1,744,000
2,340,000
1,260,000
1,301,000
1,612,000
1,176,000
1,238,000
1,276,000
1,257,000
1,206,000
1,155,000
1,170,000
1,175,000
1,528,000
1,382,000
1,504,000
1,375,000
1,643,000
1,434,000
1,966,000
1,668,000
1,431,000
1,284,000
1,396,000
1,842,000
1,515,000
1,446,000
1,511,000
1,782,000
1,696,000
1,349,000
1,495,000
1,743,000
1,314,000
1,365,000
1,620,000
1,411,000
1,235,000
1,302,000
1,172,000
2,589,000
3,598,000
3,284,000
2,777,000
4,061,000
5,373,000
5,437,000
5,146,000
4,833,000
5,384,000
232,000
108,000
656,000
656,000108,000232,0005,384,0004,833,0005,146,0005,437,0005,373,0004,061,0002,777,0003,284,0003,598,0002,589,0001,172,0001,302,0001,235,0001,411,0001,620,0001,365,0001,314,0001,743,0001,495,0001,349,0001,696,0001,782,0001,511,0001,446,0001,515,0001,842,0001,396,0001,284,0001,431,0001,668,0001,966,0001,434,0001,643,0001,375,0001,504,0001,382,0001,528,0001,175,0001,170,0001,155,0001,206,0001,257,0001,276,0001,238,0001,176,0001,612,0001,301,0001,260,0002,340,0001,744,0001,307,0001,275,0001,415,0001,990,000000
   > Long-term Liabilities 
0
0
0
2,518,000
2,390,000
2,412,000
2,288,000
2,249,000
2,363,000
2,379,000
2,422,000
2,661,000
2,103,000
2,156,000
2,082,000
2,925,000
3,021,000
3,105,000
3,038,000
2,841,000
3,644,000
3,513,000
3,411,000
3,205,000
3,133,000
2,980,000
3,006,000
2,898,000
2,904,000
3,337,000
3,432,000
3,352,000
3,407,000
3,246,000
3,098,000
2,529,000
3,263,000
3,143,000
2,922,000
2,734,000
3,903,000
3,684,000
3,641,000
4,222,000
4,963,000
5,093,000
5,033,000
5,105,000
5,852,000
5,773,000
5,835,000
6,888,000
6,657,000
6,840,000
6,688,000
6,792,000
7,882,000
7,593,000
7,425,000
6,778,000
6,778,0007,425,0007,593,0007,882,0006,792,0006,688,0006,840,0006,657,0006,888,0005,835,0005,773,0005,852,0005,105,0005,033,0005,093,0004,963,0004,222,0003,641,0003,684,0003,903,0002,734,0002,922,0003,143,0003,263,0002,529,0003,098,0003,246,0003,407,0003,352,0003,432,0003,337,0002,904,0002,898,0003,006,0002,980,0003,133,0003,205,0003,411,0003,513,0003,644,0002,841,0003,038,0003,105,0003,021,0002,925,0002,082,0002,156,0002,103,0002,661,0002,422,0002,379,0002,363,0002,249,0002,288,0002,412,0002,390,0002,518,000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,638,000
1,694,000
239,398
223,210
197,688
201,642
178,535
161,488
194,281
174,991
1,014,000
1,014,000
1,063,000
1,009,000
1,137,000
1,145,000
1,475,000
1,579,000
1,548,000
1,746,000
2,851,000
2,413,000
2,633,000
2,650,000
2,885,000
0
2,748,000
0
0
002,748,00002,885,0002,650,0002,633,0002,413,0002,851,0001,746,0001,548,0001,579,0001,475,0001,145,0001,137,0001,009,0001,063,0001,014,0001,014,000174,991194,281161,488178,535201,642197,688223,210239,3981,694,0001,638,0000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
5,831,000
6,120,000
6,749,000
7,287,000
7,824,000
7,745,000
8,105,000
8,363,000
8,809,000
8,598,000
8,847,000
9,192,000
9,555,000
9,638,000
10,045,000
10,578,000
11,054,000
10,637,000
10,821,000
11,067,000
11,269,000
11,254,000
11,183,000
11,084,000
11,580,000
10,619,000
10,949,000
10,958,000
11,732,000
10,940,000
10,663,000
10,723,000
11,254,000
10,219,000
10,707,000
10,945,000
11,425,000
10,914,000
11,010,000
11,192,000
11,468,000
10,752,000
10,804,000
10,800,000
11,233,000
10,770,000
10,903,000
11,566,000
11,827,000
11,297,000
12,099,000
13,656,000
13,837,000
12,879,000
13,386,000
14,484,000
13,978,000
13,978,00014,484,00013,386,00012,879,00013,837,00013,656,00012,099,00011,297,00011,827,00011,566,00010,903,00010,770,00011,233,00010,800,00010,804,00010,752,00011,468,00011,192,00011,010,00010,914,00011,425,00010,945,00010,707,00010,219,00011,254,00010,723,00010,663,00010,940,00011,732,00010,958,00010,949,00010,619,00011,580,00011,084,00011,183,00011,254,00011,269,00011,067,00010,821,00010,637,00011,054,00010,578,00010,045,0009,638,0009,555,0009,192,0008,847,0008,598,0008,809,0008,363,0008,105,0007,745,0007,824,0007,287,0006,749,0006,120,0005,831,000000
   Common Stock
0
0
0
650,000
650,000
650,000
650,000
650,000
650,000
650,000
650,000
650,000
650,000
650,000
650,000
650,000
650,000
639,000
639,000
639,000
639,000
639,000
639,000
639,000
626,000
626,000
626,000
626,000
620,000
620,000
620,000
620,000
610,000
610,000
610,000
610,000
610,000
594,000
594,000
594,000
582,000
582,000
582,000
582,000
570,000
570,000
570,000
570,000
570,000
564,000
564,000
564,000
564,000
562,000
562,000
562,000
562,000
562,000
562,000
562,000
562,000562,000562,000562,000562,000562,000562,000564,000564,000564,000564,000570,000570,000570,000570,000570,000582,000582,000582,000582,000594,000594,000594,000610,000610,000610,000610,000610,000620,000620,000620,000620,000626,000626,000626,000626,000639,000639,000639,000639,000639,000639,000639,000650,000650,000650,000650,000650,000650,000650,000650,000650,000650,000650,000650,000650,000650,000000
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,086,000
213,000
35,000
-76,000
109,000
0
0109,000-76,00035,000213,0001,086,000000000000000000000000000000000000000000000000000000000
   Capital Surplus 000000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
-1,470,000
-1,266,000
-1,079,000
-1,005,000
-939,000
-1,012,000
-1,118,000
-1,272,000
-1,249,000
-1,450,000
-1,631,000
-1,833,000
432,000
539,000
371,000
290,000
169,000
68,000
124,000
378,000
421,000
911,000
674,000
482,000
558,000
286,000
409,000
350,000
629,000
632,000
125,000
-121,000
-217,000
-391,000
-163,000
-233,000
-112,000
67,000
-41,000
173,000
76,000
66,000
-105,000
-366,000
-600,000
-375,000
-422,000
-258,000
-40,000
250,000
626,000
1,086,000
213,000
35,000
-76,000
109,000
-339,000
-339,000109,000-76,00035,000213,0001,086,000626,000250,000-40,000-258,000-422,000-375,000-600,000-366,000-105,00066,00076,000173,000-41,00067,000-112,000-233,000-163,000-391,000-217,000-121,000125,000632,000629,000350,000409,000286,000558,000482,000674,000911,000421,000378,000124,00068,000169,000290,000371,000539,000432,000-1,833,000-1,631,000-1,450,000-1,249,000-1,272,000-1,118,000-1,012,000-939,000-1,005,000-1,079,000-1,266,000-1,470,000000



Balance Sheet

Currency in DKK. All numbers in thousands.




Cash Flow

Currency in DKK. All numbers in thousands.




Income Statement

Currency in DKK. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue17,899,000
Cost of Revenue-8,177,000
Gross Profit9,722,0009,722,000
 
Operating Income (+$)
Gross Profit9,722,000
Operating Expense-5,258,000
Operating Income4,552,0004,464,000
 
Operating Expense (+$)
Research Development2,017,000
Selling General Administrative959,000
Selling And Marketing Expenses2,365,000
Operating Expense5,258,0005,341,000
 
Net Interest Income (+$)
Interest Income90,000
Interest Expense-173,000
Other Finance Cost-66,000
Net Interest Income-149,000
 
Pretax Income (+$)
Operating Income4,552,000
Net Interest Income-149,000
Other Non-Operating Income Expenses0
Income Before Tax (EBT)3,909,0005,195,000
EBIT - interestExpense = 4,281,000
3,894,000
3,197,000
Interest Expense173,000
Earnings Before Interest and Taxes (EBIT)4,454,0004,082,000
Earnings Before Interest and Taxes (EBITDA)5,843,000
 
After tax Income (+$)
Income Before Tax3,909,000
Tax Provision-870,000
Net Income From Continuing Ops3,039,0003,039,000
Net Income3,024,000
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses13,435,000
Total Other Income/Expenses Net-643,000149,000
 

Technical Analysis of Novozymes
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Novozymes. The general trend of Novozymes is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Novozymes's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Novozymes AS.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 61.86 < 62.21 < 63.19.

The bearish price targets are: 55.54 > 55.48 > 54.31.

Tweet this
Novozymes AS Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Novozymes AS. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Novozymes AS Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Novozymes AS.

Novozymes AS Daily Moving Average Convergence/Divergence (MACD) ChartNovozymes AS Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Novozymes AS. The current adx is .

Novozymes AS Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Novozymes AS.

Novozymes AS Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Novozymes AS.

Novozymes AS Daily Relative Strength Index (RSI) ChartNovozymes AS Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Novozymes AS.

Novozymes AS Daily Stochastic Oscillator ChartNovozymes AS Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Novozymes AS.

Novozymes AS Daily Commodity Channel Index (CCI) ChartNovozymes AS Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Novozymes AS.

Novozymes AS Daily Chande Momentum Oscillator (CMO) ChartNovozymes AS Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Novozymes AS.

Novozymes AS Daily Williams %R ChartNovozymes AS Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Novozymes AS.

Novozymes AS Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Novozymes AS.

Novozymes AS Daily Average True Range (ATR) ChartNovozymes AS Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Novozymes AS.

Novozymes AS Daily On-Balance Volume (OBV) ChartNovozymes AS Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Novozymes AS.

Novozymes AS Daily Money Flow Index (MFI) ChartNovozymes AS Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Novozymes AS.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-17STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-19CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-31ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-02ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-20BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Novozymes AS Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Novozymes AS based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose59.050
Total1/1 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Novozymes with someone you think should read this too:
  • Are you bullish or bearish on Novozymes? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Novozymes? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Novozymes AS

I send you an email if I find something interesting about Novozymes AS.


Comments

How you think about this?

Leave a comment

Stay informed about Novozymes AS.

Receive notifications about Novozymes AS in your mailbox!